ERBB2 and gastroesophageal junction adenocarcinoma: These findings highlight the PD-L1 TAP score’s crucial role in treatment decisions for HER2-negative advanced G/GEJ adenocarcinoma with TLE-CHM, suggesting its use to tailor treatment plans for better therapeutic and economic outcomes.